Aquestive Therapeutics Inc (NASDAQ: AQST) kicked off on Tuesday, up 3.55% from the previous trading day, before settling in for the closing price of $3.10. Over the past 52 weeks, AQST has traded in a range of $2.24-$6.23.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -0.52% over the last five years. While this was happening, its average annual earnings per share was recorded -235.60%. With a float of $77.61 million, this company’s outstanding shares have now reached $91.18 million.
The firm has a total of 135 workers. Let’s measure their productivity. In terms of profitability, gross margin is 69.39%, operating margin of -35.83%, and the pretax margin is -59.58%.
Aquestive Therapeutics Inc (AQST) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Aquestive Therapeutics Inc is 14.88%, while institutional ownership is 46.02%. The most recent insider transaction that took place on Nov 26 ’24, was worth 214. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $4.87, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 15 ’24, when Company’s Chief Innovation/Tech Officer sold 50,000 for $6.00, making the entire transaction worth $300,000. This insider now owns 984,476 shares in total.
Aquestive Therapeutics Inc (AQST) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -235.60% per share during the next fiscal year.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Take a look at Aquestive Therapeutics Inc’s (AQST) current performance indicators. Last quarter, stock had a quick ratio of 5.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Analysing the last 5-days average volume posted by the [Aquestive Therapeutics Inc, AQST], we can find that recorded value of 1.42 million was lower than the volume posted last year of 1.68 million. As of the previous 9 days, the stock’s Stochastic %D was 32.74%. Additionally, its Average True Range was 0.22.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 8.80%, which indicates a significant decrease from 30.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.09% in the past 14 days, which was lower than the 66.39% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.04, while its 200-day Moving Average is $3.90. Now, the first resistance to watch is $3.26. This is followed by the second major resistance level at $3.31. The third major resistance level sits at $3.40. If the price goes on to break the first support level at $3.12, it is likely to go to the next support level at $3.03. Now, if the price goes above the second support level, the third support stands at $2.98.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
The company with the Market Capitalisation of 292.68 million has total of 91,178K Shares Outstanding. Its annual sales at the moment are 50,580 K in contrast with the sum of -7,870 K annual income. Company’s last quarter sales were recorded 13,540 K and last quarter income was -11,510 K.
